James Woodruff Lillie is a corporate insider at MapLight Therapeutics, Inc. (MPLT). Lillie has reported 7 insider filings with the SEC since 2025. The most recent filing was in July 2026.
Every role James Woodruff Lillie has reported on a Form 4, reconstructed from the filings themselves. Reporting insiders must state their relationship to the issuer (officer title, director seat, or 10% ownership) on every filing.
MapLight Therapeutics, Inc. (MPLT)3 filingsUpdated Aug 30, 2026
James Woodruff Lillie is Chief Scientific Officer of MapLight Therapeutics, Inc. (MPLT). 9 SEC Form 4 filings on record going back to 2025, most recently on 19 August 2026. Most recent open-market trade: sold $277K of MPLT on 5 August 2026. Lifetime open-market sales: $2.56M.
Every recent SEC Form 4 transaction James Woodruff Lillie has reported, most recent first.
InsiderAlpha's records for James Woodruff Lillie go back to 2025: 9 primary Form 4 filings, an average of 4.5 per year. 10 recorded transactions carry a Rule 10b5-1 flag, meaning they were pre-scheduled under a written trading plan rather than discretionary.
Insiders who reported open-market trades in the last 12 months at the companies James Woodruff Lillie files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
James Woodruff Lillie is a corporate insider, tracked as Chief Scientific Officer of MapLight Therapeutics, Inc. (MPLT). InsiderAlpha holds 9 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
3 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases and 20 open-market sales ($2.56M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial